Share on LinkedInShare on LinkedIn

ARTICLE · 09 AUGUST 2023

3 Recent Antitrust Shifts And Their Impact On Life Sciences

The antitrust landscape has changed significantly over the course of President Joe Biden's presidency and top antitrust regulators show no signs of easing up on enforcement across industries.

United StatesAntitrust/Competition Law

The antitrust landscape has changed significantly over the course of President Joe Biden's presidency and top antitrust regulators show no signs of easing up on enforcement across industries.

The life sciences industry is no exception, as Federal Trade Commission (FTC) Chair Lina Khan and Department of Justice (DOJ) antitrust head Jonathan Kanter continue to set their sights on drug company mergers and acquisitions they believe would damage consumers and the U.S. economy. These two regulators have also signaled intentions to expand their use of antitrust laws in more instances, including everything from unfair competition to wages and labor.

Khan and Kanter are responding to President Biden's 2021 executive order on "promoting competition in the American economy" that encourages the DOJ and FTC "to enforce the antitrust laws fairly and vigorously," as well as carrying out their own philosophies that antitrust enforcement has been lax. Government agencies are also

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from